医学临床研究
  2025年7月20日 星期日           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2024, Vol. 41 Issue (1): 25-28    DOI: 10.3969/j.issn.1671-7171.2024.01.007
  论著 本期目录 | 过刊浏览 | 高级检索 |
外周血miR-143、miR-33a表达与膀胱癌患者临床预后的相关性
高永辉, 彭贝贝
许昌医院,河南 许昌 461000
Correlation between the Expression of miR-143 and miR-33a in Peripheral Blood and the Clinical Prognosis of Bladder Cancer Patients
GAO Yonghui, PENG Beibei
Xuchang Hospital, Xuchang Henan 461000
全文: PDF (1375 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】 探讨外周血miR-143、miR-33a表达与膀胱癌患者临床预后的相关性。【方法】 选取2017年5月至2021年4月本院收治的60例膀胱癌患者(观察组),另选取同期体检的60例健康志愿者作为对照组。比较两组研究对象外周血miR-143、miR-33a表达水平及不同病理特征患者外周血miR-143、miR-33a表达水平,评价外周血miR-143、miR-33a对膀胱癌的诊断价值,比较外周血miR-143、miR-33a不同表达膀胱癌患者生存曲线,分析外周血miR-143、miR-33a表达与膀胱癌患者死亡风险的关系。【结果】 观察组患者外周血miR-143、miR-33a表达水平低于对照组患者,差异有统计学意义(P<0.05)。不同临床分期、组织分化程度、初发与复发及有无远处转移患者外周血miR-143、miR-33a表达水平比较,差异有统计学意义(P<0.05)。外周血miR-143、miR-33a联合诊断膀胱癌的曲线下面积为0.922,显著高于miR-143、miR-33a单一指标(P<0.05)。外周血miR-143、miR-33a低表达患者的术后3年生存率分别低于外周血miR-143、miR-33a高表达患者(P<0.05)。外周血miR-143、miR-33a低表达患者术后3年死亡风险是高表达患者的4.550倍、5.223倍(P<0.05)。【结论】 膀胱癌患者miR-143、miR-33a表达下调,与病理特征密切相关,检测其表达水平有助于评估患者预后情况,具有较高临床价值。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
高永辉
彭贝贝
关键词 膀胱肿瘤/病理学微RNAs预后    
Abstract:【Objective】 To investigate the relationship between the expression of miR-143 and miR-33a in peripheral blood and the clinical prognosis of bladder cancer patients. 【Methods】 A total of 60 patients with bladder cancer admitted to our hospital from May 2017 to April 2021 (observation group) were selected, and 60 healthy volunteers who underwent physical examination in the same period were selected as the control group. The expression levels of miR-143 and miR-33a in the peripheral blood of the two groups of subjects and the expression levels of miR-143 and miR-33a in the peripheral blood of patients with different pathological characteristics were compared. The diagnostic value of miR-143 and miR-33a in the peripheral blood for bladder cancer was evaluated. The survival curves of bladder cancer patients with different expressions of miR-143 and miR-33a in the peripheral blood were compared. The relationship between the expression of miR-143 and miR-33a in the peripheral blood and the death risk of bladder cancer patients was analyzed.【Result】 The expression levels of miR-143 and miR-33a in the peripheral blood of the observation group were lower than those of the control group, and the difference was statistically significant (P<0.05). The expression levels of miR-143 and miR-33a in peripheral blood of patients with different clinical stages, degree of tissue differentiation, initial and recurrent stages, and presence or absence of distant metastasis were compared, and the differences were statistically significant (P<0.05). The area under the curve of miR-143 and miR-33a in the combined diagnosis of bladder cancer was 0.922, significantly higher than that of miR-143 and miR-33a (P<0.05). The postoperative 3-year survival rates of patients with low expression of miR-143 and miR-33a in peripheral blood were lower than those of patients with high expression of miR-143 and miR-33a in peripheral blood (P<0.05). The 3-year postoperative mortality risk of patients with low expression of miR-143 and miR-33a in peripheral blood is 4.550 times and 5.223 times higher than that of patients with high expression (P<0.05).【Conclusion】 The expression of miR-143 and miR-33a in the peripheral blood of patients with bladder cancer is down regulated, which is closely related to the pathological characteristics. The detection of their expression level is helpful to evaluate the prognosis of patients, and has high clinical value.
Key wordsUrinary Bladder Neoplasms/PA    MicroRNAs    Prognosis
收稿日期: 2023-05-08     
中图分类号:  R694  
引用本文:   
高永辉, 彭贝贝. 外周血miR-143、miR-33a表达与膀胱癌患者临床预后的相关性[J]. 医学临床研究, 2024, 41(1): 25-28.
GAO Yonghui, PENG Beibei. Correlation between the Expression of miR-143 and miR-33a in Peripheral Blood and the Clinical Prognosis of Bladder Cancer Patients. JOURNAL OF CLINICAL RESEARCH, 2024, 41(1): 25-28.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2024.01.007     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2024/V41/I1/25
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn